| Similar Articles |
|---|
 |
The Motley Fool
July 29, 2011
Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start.   |
The Motley Fool
May 18, 2011
Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool
January 19, 2012
Brian Orelli |
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
August 4, 2010
Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool
July 27, 2011
Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
October 31, 2011
Brian Orelli |
When Getting Beat Down Is No Big Deal Merck is getting smacked down by Vertex Pharmaceuticals in the hepatitis C market, but it has the bulk to take a beating. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool
June 14, 2011
Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
May 17, 2011
Luke Timmerman |
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. |
The Motley Fool
November 2, 2011
David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
Chemistry World
October 30, 2013
Phillip Broadwith |
Vertex to cut 370 jobs US biopharmaceutical firm Vertex is cutting 370 jobs as it faces a drop in demand for its hepatitis C drug Incivek (telaprevir). |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
June 9, 2011
Brian Orelli |
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
July 25, 2007
Brian Lawler |
Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report. |
The Motley Fool
January 11, 2012
Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running. |
The Motley Fool
September 26, 2007
Brian Orelli |
Second-Line Isn't Second Best Schering-Plough gets a positive recommendation for its hepatitis C drugs as a second-line treatment in Europe. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
April 23, 2008
Brian Lawler |
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. |
The Motley Fool
January 24, 2008
Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool
April 28, 2011
Brian Orelli |
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. |
The Motley Fool
March 28, 2008
Brian Orelli |
The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug. |
The Motley Fool
April 25, 2008
Brian Lawler |
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. |
The Motley Fool
December 15, 2011
Luke Timmerman |
Vertex Names Jeff Leiden As New CEO, Staring Down Tough New Competition What does new leadership mean for Vertex's future? |
The Motley Fool
March 28, 2008
Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. |
The Motley Fool
January 15, 2008
Brian Orelli |
Ideal Results From Schering A post-marketing clinical trial from Schering on its hepatitis C virus treatment Pegintron yields better results for the company, although not without some controversy. Investors, take note. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
June 9, 2011
Brian D. Pacampara |
Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
November 6, 2007
Brian Lawler |
No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns? |
The Motley Fool
April 1, 2008
Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool
November 30, 2011
David Williamson |
Health Care's 5 Worst November Flops These stocks had a terrible month. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
The Motley Fool
March 20, 2009
Brian Orelli |
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. |
The Motley Fool
May 23, 2008
Brian Lawler |
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
May 12, 2008
Brian Lawler |
Hep C Drugs Slug It Out Does Vertex's telaprevir really trump Schering's boceprevir? |
